Johnson & Johnson Pacific has confirmed that it will discontinue its codeine-containing Codral formulation
The current formulation containing low-dose codeine is being phased out, a spokesperson for the company told the AJP today.
“To meet the implementation date of 1 February 2018 and to ensure a stable supply of Codral products to consumers, a range of codeine-free Codral products is available to consumers now.
“Codral will continue to be formulated with high-quality ingredients that provide efficacious relief from cold and flu symptoms, and consumers can confidently rely on the wide range of Codral cold and flu medicines.
“Current formulations that include codeine will remain in market until 1 February 2018 or until stock runs out, whichever occurs first.”
GSK announced in March 2017 that it would pull its OTC codeine range ahead of the upschedule, including the Panadeine range, while Bayer is also discontinuing codeine-containing cold and flu tablets.
In August 2017, NPS MedicineWise revealed figures which showed that Codral Cold and Flu tablets were among those misused by Ausralians.
Twelve per cent of respondents to its survey said that they had exceeded the recommended daily dose of widely-used medicines such as paracetamol/codeine, ibuprofen/codeine and Codral Cold and Flu tablets.